江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥药业 编号：20230707 √ 特定对象调研 □ 分析师会议 投资者关系活动 □ 媒体采访 □ 业绩说明会 类别 □ 新闻发布会 √ 路演活动 √ 现场参观 □ 其他 宝盈基金、长江养老、东兴基金、广发证券、华龙证券、华夏保险、 参与单位名称及 盘京投资、青岛恒泽睿、泉果基金、兴全基金、睿远基金、招商证 人员姓名 券、中阅资本（以上排名不分先后） 时间 2023 年 07 月 06 日 10:00-14:00 地点 江西富祥药业股份有限公司、江西祥太生命科学有限公司、景德镇 富祥生命科技有限公司 上市公司接待人 董事长兼总经理 包建华、副董事长 李惠跃、董事 柯丹、副总经理 员姓名 陈应惠、副总经理兼董事会秘书 彭云 投资者关系活动的主要内容如下： 本次交流会议主要采取问答的形式，公司参会人员就投资者关 注的问题给予现场解答，帮助投资者更全面地了解公司发展情况， 公司参会人员在会议过程中遵循了投资者关系管理、上市公司信息 披露等规定。 投资者关系活动 首先公司董事长包建华先生在富祥科技会议室对各位投资者的 主要内容介绍 到 ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥药业 编号：20230523 √ 特定对象调研 □ 分析师会议 投资者关系活动 □ 媒体采访 □ 业绩说明会 类别 □ 新闻发布会 √ 路演活动 √ 现场参观 □ 其他 华夏保险、国联证券、正心谷资本、华商基金、青岛恒泽睿、安信 参与单位名称及 证券、东方财富证券、光大证券、海通证券、华能贵诚信托、宁波 人员姓名 悦扬、宁波星通、上海信统电器、上海中铸、上海九颂山河、唐山 千百十投资、同德乾元、中璟沃盛、唐宁、胡鸿等 26 家机构及个人 投资者（以上排名不分先后） 时间 2023 年 05 月 23 日 8:30-12:00 地点 江西富祥药业股份有限公司、江西祥太生命科学有限公司、景德镇 富祥生命科技有限公司 上市公司接待人 董事长兼总经理 包建华、副董事长 李惠跃、副总经理 陈应惠、副 员姓名 总经理兼董事会秘书 彭云及公司相关领导 投资者关系活动的主要内容如下： 本次交流会议主要采取问答的形式，公司参会人员就投资者关 注的问题给予现场解答，帮助投资者更全面地了解公司发展情况， 公司参会人员在会议过程中遵循了投资者关系管 ...

优势地位，通过技术改造，力行降本增效，提升产品毛利率； 第二，扩大原有产品在国内外的注册，同时进行新产品的国内 外注册，拓展现有产品新客户新市场，开发新产品新增长；第 三，对锂电池电解液添加剂板块，持续工艺优化和技术创新， 打造绿色生产工艺和提升本质安全水平，降低综合生产成本， 提高产品市场竞争力。 3、现在 vc 价格多少一吨，公司现有产能 8000 吨产能。 有盈利了吗？ 答：投资者您好，经过一年的生产探索，公司 VC 项目通 过工艺和设备改进，原料单耗得到下降，产品质量持续稳定， 产量稳步提升，销售客户扩大，销量得到增长，市场竞争力逐 步提升。 4、请问董事长年报里有关光刻胶订单已经交付中，有无 新增订单？多少量？谢谢 | | □特定对象调研 □分析师会议 | | | | --- | --- | --- | --- | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | | 类别 | □新闻发布会 □路演活动 | | | | | □现场参观 □其他 | | | | 参与单位名称及 人员姓名 | 参加公司 年度网上业绩说明会的投资者 2022 | | | | 时间 | 年 月 日 2023 15 ...

证券代码：300497 证券简称：富祥药业 公告编号：2023-046 江西富祥药业股份有限公司 关于参加江西辖区上市公司2023年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，江西富祥药业股份有限公司（以下简称"公 司"）将参加由江西证监局、江西省上市公司协会与深圳市全景网络有限公司联合举 办的"2023年江西辖区上市公司投资者集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP，参与本 次互动交流，活动时间为2023年5月19日（周五）14:30—17:00。届时公司高管将在线 就公司2022年度业绩、公司治理、发展战略、经营情况、融资计划、股权激励和可持 续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 江西富祥药业股份有限公司 董事会 2023 年 5 月 15 日 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[24]. - The gross profit margin improved to 45%, up from 42% in the previous year, indicating enhanced operational efficiency[24]. - The company achieved a net profit of RMB 300 million, reflecting a 10% increase compared to the previous year[24]. - The company's operating revenue for 2022 was ¥1,647,263,426.90, an increase of 15.23% compared to ¥1,429,542,874.53 in 2021[32]. - The net profit attributable to shareholders was a loss of ¥141,471,326.16 in 2022, a decrease of 389.72% from a profit of ¥48,830,662.43 in 2021[32]. - The net cash flow from operating activities was a negative ¥120,850,690.10, down 267.10% from ¥72,321,556.16 in 2021[32]. - The company reported a basic earnings per share of -¥0.26 in 2022, a decline of 388.89% from ¥0.09 in 2021[32]. - The company recognized investment losses of CNY 82.15 million due to policy impacts on its investment in a healthcare partnership[80]. - The company reported a total revenue of 134,970,809 RMB for the year 2022, with a net profit of 2,262,000 RMB, indicating a decrease of 115,200 RMB compared to the previous year[163]. Market Expansion and Product Development - The company plans to launch three new products in 2023, focusing on antibiotic and anti-infection therapies, aiming for a market share increase of 10%[24]. - Future guidance estimates revenue growth of 12% to 15% for 2023, driven by new product launches and market expansion efforts[24]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of RMB 300 million allocated for this purpose[24]. - The company is actively pursuing domestic and international product registrations to attract new customers and strengthen quality control[10]. - The company is focusing on expanding its market presence and enhancing its product offerings through new product development and technological advancements[166]. - The company aims to strengthen its lithium battery electrolyte additive segment by developing a series of products including VC, FEC, and BOB, and enhancing production capacity[140]. - The company has initiated a strategic acquisition of a smaller pharmaceutical firm, which is expected to enhance its product portfolio and increase annual revenue by 150 million yuan[176]. Research and Development - The company emphasizes the importance of R&D and plans to increase investment in product innovation and market research to ensure future growth[13]. - The company is investing RMB 200 million in R&D for new technologies, particularly in the field of β-lactam antibiotics[24]. - Research and development expenses increased by 30% in 2022, totaling 180 million yuan, reflecting the company's commitment to innovation[176]. - The company has established a new partnership with a leading research institution to enhance its drug development capabilities[176]. Operational Efficiency and Cost Management - The company aims to optimize production processes and improve automation to reduce raw material consumption and enhance production efficiency[10]. - The company has implemented a standardized procurement process to control raw material costs and ensure timely production, aligning procurement plans with sales forecasts[64]. - The company plans to implement comprehensive cost reduction and efficiency enhancement measures across various business modules in 2023[139]. - The company has optimized its production processes and is exploring energy utilization and circular economy strategies to further reduce costs[55]. Environmental and Compliance Commitment - The company is committed to environmental protection and has implemented measures to reduce pollution and comply with stricter regulations[12]. - The company emphasizes the importance of safety production management, aiming for a balance between safety and economic development[143]. - The company has established a comprehensive internal control system in compliance with relevant laws and regulations to enhance corporate governance and risk management[144]. - The company is committed to transparent information disclosure, ensuring all shareholders have equal access to information[156]. Financial Management and Governance - The company has a governance structure that includes a board of directors with 7 members, including 3 independent directors, ensuring compliance with legal requirements[151]. - The company has implemented a performance evaluation system for senior management, linking their performance directly to compensation[155]. - The total pre-tax compensation for the chairman and general manager, Bao Jianhua, is 132.02 million[178]. - The company has established a long-term mechanism for hidden danger investigation and rectification in safety management[143]. Challenges and Risks - The company experienced significant profit pressure due to rising raw material prices, public health events, and decreased product prices from newly launched projects, leading to a substantial decline in key financial metrics[8]. - The company acknowledges risks related to market competition, particularly in the pharmaceutical manufacturing sector, and is focused on developing a sustainable product portfolio[12]. - The company is aware of the risks associated with raw material price fluctuations and is taking steps to stabilize procurement costs[15]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the audit report for the most recent year[32].

Financial Performance - The company's revenue for Q1 2023 was ¥397.92 million, a decrease of 1.10% compared to ¥402.33 million in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥30.15 million, representing a decline of 207.86% from a profit of ¥27.95 million in the previous year[5]. - The basic and diluted earnings per share were both -¥0.06, down 220.00% from ¥0.05 in the same quarter last year[5]. - The company's net profit for the period was -¥33.59 million, a decline of 244.28% compared to a profit of ¥23.28 million in the previous year, mainly due to a decrease in product prices and gross profit margins[9]. - Total operating revenue for Q1 2023 was CNY 397,918,173.64, a decrease of 1.03% compared to CNY 402,333,468.40 in the same period last year[27]. - Net profit for Q1 2023 was a loss of CNY 33,590,833.08, compared to a profit of CNY 23,281,932.07 in Q1 2022, indicating a significant decline in profitability[29]. - Total revenue from sales of goods and services received in Q1 2023 was CNY 124,519,192.17, a decrease from CNY 246,083,864.83 in Q1 2022[31]. Cash Flow and Assets - The net cash flow from operating activities was -¥94.83 million, a decrease of 93.69% compared to -¥48.96 million in the same period last year[5]. - Cash and cash equivalents at the end of Q1 2023 were CNY 689,922,521.41, down from CNY 978,027,566.82 at the beginning of the year, representing a decline of 29.48%[24]. - Total current assets decreased to CNY 1,953,998,677.02 from CNY 2,229,278,305.12, reflecting a reduction of 12.34%[24]. - Total liabilities decreased to CNY 2,207,864,324.57 from CNY 2,370,197,741.24, a decline of 6.86%[25]. - The company's total assets decreased to CNY 4,865,366,311.20 from CNY 5,059,834,182.46, a decline of 3.84%[25]. - Cash flow from operating activities showed a net outflow of CNY 94,831,724.81 in Q1 2023, worsening from a net outflow of CNY 48,959,708.08 in Q1 2022[32]. - Cash and cash equivalents at the end of Q1 2023 were CNY 619,312,659.18, down from CNY 1,218,580,837.61 at the end of Q1 2022, a decrease of approximately 49%[32]. Costs and Expenses - Total operating costs for Q1 2023 were CNY 431,474,684.77, an increase from CNY 372,752,389.58 in Q1 2022, representing a growth of approximately 15.8%[28]. - Research and development expenses increased to CNY 19,477,717.76 in Q1 2023 from CNY 16,774,533.75 in Q1 2022, reflecting a growth of about 10.1%[28]. - Financial expenses increased by 187.22% to ¥10.87 million due to higher interest expenses from increased borrowings[9]. - The company reported a significant decrease in other income, down 69.18% to ¥1.05 million, primarily due to reduced government subsidies received[9]. Strategic Focus and Development - The decline in performance was primarily due to high raw material prices and decreased product prices, which compressed profit margins[14]. - The company plans to focus on cost reduction and efficiency improvement across various business modules to enhance market competitiveness[16]. - In 2023, the company aims to strengthen its lithium battery electrolyte additive segment and expand its product line with VC, FEC, and BOB series products[17]. - The company is also developing new electronic chemicals and specialty materials to cultivate potential in the new materials sector[17]. - The company emphasizes safety production as a critical aspect of its operational strategy[19]. - The company emphasizes the importance of safety production management and compliance governance as key drivers for sustainable development[21]. - The company is committed to enhancing its safety culture and management systems to ensure a safe working environment[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,828[12]. - The company holds 11,355,900 shares in its repurchase account, accounting for 2.06% of the total share capital[13]. - A proposal for a simplified procedure to issue up to RMB 300 million in new shares, not exceeding 20% of the latest year's net assets, will be presented to the shareholders' meeting[18]. Audit Information - The company did not undergo an audit for the Q1 2023 report[33].

证券代码：300497 证券简称：富祥药业 公告编号：2023-044 江西富祥药业股份有限公司 关于举行2022年年度报告业绩网上说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）2022 年年度报告全文及其报告 摘要于 2023 年 4 月 26 日刊登于中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）。 为了更好地与广大投资者进行交流，使投资者能够进一步了解公司的生产经营情 况，公司定于2023年5月16日（星期二）15：00-17：00在全景网举办公司2022年年度 业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆全景网 "投资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明会。 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 特此公告。 江西富祥药业股份有限公司 董事会 2023 年 4 月 25 日 出席本次说明会的人员有：公司董事长兼总经理包建华先生、独立董事刘洪先生、 财务总监杨光 ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥股份 编号：20160628 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 参与单位名称及 | 西南证券 周平 | | | 人员姓名 | 泰康资产 王晓锋 | | | | 融通基金 曹姗姗 | | | 时间 | 2016 年 6 月 28 | 日 10:00-12:00 | | 地点 | 公司本部 | | | 上市公司接待人 | | | | 员姓名 | 董事会秘书 黄晓东 | | | 投资者关系活动 | | 首先，董事会秘书介绍了公司的基本情况，以及未来的 | | 主要内容介绍 | 发展规划。 | | | | | 其次，是投资者互动环节： | | ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥股份 编号：20170116 | --- | --- | --- | --- | |----------------|---------------------------|--------------------------|--------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | | √ 现场参观 □其他 | | | | 参与单位名称及 | 中融基金管理有限公司 杜伟 | | | | 人员姓名 | 招商证券 李勇剑 | | | | | 方正证券 蒋一樊 | | | | | 平安证券 梁欢 | | | | | 中泰证券 池陈森 | | | | 时间 | 2017 年 1 月 16 | 日 11:00-15:30 | | | 地点 | 公司本部 | | | | 上市公司接待人 | | | | | 员姓名 | ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥药业 编号：20200521 | --- | --- | --- | |-----------------------|------------------------------|------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 参与单位名称及 | | 长城国瑞证券 郑学军；长城国瑞证券黄文忠；长城国瑞证 | | 人员姓名 | 券 胡晨曦 | | | 时间 | 2020 年 5 月 21 日 | 9:30-11:30 | | 地点 | 公司本部 | | | | | | | 上市公司接待人 员姓名 | | 董事会秘书 黄晓东；证券事务代表 彭云 | | 投资者关系活动 | | 一、介绍公司基本情况： | | 主要内容介绍 | 基本情况： | | | | 公司成立于 | ...